VolitionRx Launches Innovative DETECSEPS Program for Sepsis Detection in France
VolitionRx Launches Innovative DETECSEPS Program for Sepsis Detection in France
VolitionRx Limited, a global leader in epigenetics, has unveiled detailed information about its groundbreaking DETECSEPS (Detection of Sepsis) program aimed at improving sepsis detection and management in emergency settings in France. This initiative has garnered governmental backing and represents a significant leap forward in tackling the global health crisis posed by sepsis, which claims approximately 21 million lives annually. The DETECSEPS program is designed to rapidly evaluate patients suspected of infection and determine who is at risk for sepsis, ensuring timely and appropriate care.
Understanding Sepsis and Its Ruinous Impact
Sepsis results from the body's exceedingly strong response to infection, leading to potential organ failure. Its rapid identification is critical; the faster clinicians can act, the greater the chances of improving patient outcomes. Cameron Reynolds, CEO of VolitionRx, emphasized the company's commitment to enhancing diagnostic methods for life-threatening conditions during the launch. "We proudly participate in the DETECSEPS Consortium,
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.